News
Bevacizumab Ups Progression-Free Survival in Ovarian Cancer
For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS).
Your search for bevacizumab returned 103 results
Drug News
Review Compares Bevacizumab vs. Ranibizumab for Macular Degeneration
The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).
News
ASCO: Continuing Avastin With 2nd-Line Chemo Ups Survival
Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy.
Drug News
Adjuvant Bevacizumab Ups Survival in Cervical Cancer
Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.
News
Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Drug News
Bevacizumab Safe, Stable for Multiple Dosing From Single Vial
No evidence of infection, inflammation when bevacizumab is stored at 4 Celsius for a week
News
Endophthalmitis Risk May Not Be Higher With Bevacizumab After All
Ophthalmic injections of bevacizumab exhibited no greater risk of endophthalmitis than injections of ranibizumab, according to a new study published in JAMA Ophthalmology.
News
Bevacizumab Offers Lasting Improvement in Macular Edema
At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT).
News
No Survival Improvement From Bevacizumab for Patients with Newly Diagnosed Glioblastoma
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.
Drugs in the Pipeline
Biosimilar Candidate Comparable to Bevacizumab in NSCLC
Amgen and Allergan announced that their biosimilar candidate ABP 215 met its primary and secondary endpoints in a Phase 3 study evaluating its efficacy and safety compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).
